Ambros Therapeutics, Inc.
PrivateLast Round
Series A
Dec 16, 2025
Total Funding Raised
$125M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ambros Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need, with its lead program targeting complex regional pain syndrome type 1 (CRPS-1).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ambros Therapeutics, Inc. Comparables
Compare Ambros Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Axsome Therapeutics Inc | 74% | |
| Abiogen Pharma | 64% | |
| Plumeria Therapeutics, Inc. | 61% |
Ambros Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 16, 2025 |
Ambros Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Enavate Sciences | Series A |
| Janus Henderson Group | Series A |
| Balyasny Asset Management L.P. | Series A |
| RA Capital Management | Series A |
| Adage Capital Partners, L.P. | Series A |
| Adage Capital Management | Series A |
| Transhuman Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 23, 2026
Grew 24% QoQ from 29 to 36 employees.
- Aug 21, 2026
Monthly visitors increased 104% MoM, reaching 2.9K.
Recent news
Latest coverage and updates
- hiresAug 27, 2026
Ambros Therapeutics, Inc. hired Scott Robertson as Board of Directors on Aug 27th '26.
- is_developingAug 27, 2026
Ambros Therapeutics, Inc. is developing neridronate program on Aug 27th '26.
- hiresAug 27, 2026
Ambros Therapeutics, Inc. hired John C. Jacobs as Board of Directors on Aug 27th '26.
- receives_financingAug 21, 2026
Ambros Therapeutics, Inc. received financing of $150M on Aug 21st '26.
Ambros Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ambros Therapeutics, Inc.'s valuation, stock price, and market status.
Is Ambros Therapeutics, Inc. a public or private company?
Ambros Therapeutics, Inc. is a private company.
What is the current stock price of Ambros Therapeutics, Inc.?
Ambros Therapeutics, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Ambros Therapeutics, Inc. worth (valuation)?
Valuation information for Ambros Therapeutics, Inc. is not publicly available.
Can I buy Ambros Therapeutics, Inc. stock?
Ambros Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ambros Therapeutics, Inc.'s last funding round?
Ambros Therapeutics, Inc.'s most recent funding round was Series A on December 16, 2025.
Who are the main investors in Ambros Therapeutics, Inc.?
Key investors in Ambros Therapeutics, Inc. include Enavate Sciences, RA Capital Management.
Will Ambros Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Ambros Therapeutics, Inc..
How can I track Ambros Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ambros Therapeutics, Inc.'s secondary market activity and sign up for updates.